Cencora vs Adapthealth: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Cencora Inc. (COR)

Q3 202613 Jul – 19 Sep 2026

▲3

Cencora lifts guidance on specialty drug strength, adds buyback and AI push

Profit outlook raised again on specialty drugs Cencora beat profit estimates and raised its full-year earnings guidance, with adjusted operating income up 17% as specialty and cancer-care businesses grew. Higher expected profits make the shares worth more to investors, which is why the stock rose.
The repeated guidance raise and profit beat are the core force lifting COR.
$1 billion buyback finished early Cencora bought back $1 billion of its own stock in the quarter, finishing a program it had planned to spread through 2026, and kept paying its dividend. Fewer shares outstanding lifts earnings per share and signals confidence, supporting the price.
Buybacks directly shrink share count and support the stock price.
New cell and gene therapy service for hospitals Cencora launched a service helping hospitals set up cell and gene therapy programs, a fast-growing area where most hospital pharmacy leaders say they are unprepared. This opens a new source of demand and fees, supporting future revenue growth.
It is a new business line that expands COR's addressable market.
AI speeds decisions, but costs and thin GLP-1 margins bite Cencora says AI roughly halves the time for some treatment decisions, a plus for its technology story. But GLP-1 drugs carry lower margins, interest costs jumped 72% after the OneOncology deal, and it lost an oncology customer, weighing on results.
It gives the fair counterweight: real positives alongside margin and cost pressures.

August 202613 Jul – 19 Sep 2026

▲3

Cencora lifts guidance on specialty drug strength, adds buyback and AI push

Profit outlook raised again on specialty drugs Cencora beat profit estimates and raised its full-year earnings guidance, with adjusted operating income up 17% as specialty and cancer-care businesses grew. Higher expected profits make the shares worth more to investors, which is why the stock rose.
The repeated guidance raise and profit beat are the core force lifting COR.
$1 billion buyback finished early Cencora bought back $1 billion of its own stock in the quarter, finishing a program it had planned to spread through 2026, and kept paying its dividend. Fewer shares outstanding lifts earnings per share and signals confidence, supporting the price.
Buybacks directly shrink share count and support the stock price.
New cell and gene therapy service for hospitals Cencora launched a service helping hospitals set up cell and gene therapy programs, a fast-growing area where most hospital pharmacy leaders say they are unprepared. This opens a new source of demand and fees, supporting future revenue growth.
It is a new business line that expands COR's addressable market.
AI speeds decisions, but costs and thin GLP-1 margins bite Cencora says AI roughly halves the time for some treatment decisions, a plus for its technology story. But GLP-1 drugs carry lower margins, interest costs jumped 72% after the OneOncology deal, and it lost an oncology customer, weighing on results.
It gives the fair counterweight: real positives alongside margin and cost pressures.

Latest13 Jul – 19 Sep 2026

▲3

Cencora lifts guidance on specialty drug strength, adds buyback and AI push

Profit outlook raised again on specialty drugs Cencora beat profit estimates and raised its full-year earnings guidance, with adjusted operating income up 17% as specialty and cancer-care businesses grew. Higher expected profits make the shares worth more to investors, which is why the stock rose.
The repeated guidance raise and profit beat are the core force lifting COR.
$1 billion buyback finished early Cencora bought back $1 billion of its own stock in the quarter, finishing a program it had planned to spread through 2026, and kept paying its dividend. Fewer shares outstanding lifts earnings per share and signals confidence, supporting the price.
Buybacks directly shrink share count and support the stock price.
New cell and gene therapy service for hospitals Cencora launched a service helping hospitals set up cell and gene therapy programs, a fast-growing area where most hospital pharmacy leaders say they are unprepared. This opens a new source of demand and fees, supporting future revenue growth.
It is a new business line that expands COR's addressable market.
AI speeds decisions, but costs and thin GLP-1 margins bite Cencora says AI roughly halves the time for some treatment decisions, a plus for its technology story. But GLP-1 drugs carry lower margins, interest costs jumped 72% after the OneOncology deal, and it lost an oncology customer, weighing on results.
It gives the fair counterweight: real positives alongside margin and cost pressures.

Adapthealth Corp (AHCO)

Q3 202616 Jul – 8 Sep 2026

▼2▲1

AdaptHealth Cuts 2026 Outlook, Sells Diabetes Unit, Swaps CFO

Q2 miss and huge 2026 guidance cut AdaptHealth badly missed second-quarter sales and profit, then slashed its 2026 revenue forecast to about $2.87 billion from $3.45–3.52 billion. The stock fell roughly 42–46% as investors lost confidence in how fast the core business is growing.
This is the single biggest new force behind AHCO's price drop this period.
Negative free cash flow and securities investigation Free cash flow turned negative at $48.4 million for the first half, down from positive $73.3 million a year earlier, partly due to a costly West Coast contract. A law firm opened an investigation into whether AdaptHealth misled investors, adding legal uncertainty.
Cash flow weakness and legal risk are new, concrete reasons investors are selling.
Selling diabetes unit to Cardinal Health for $235 million AdaptHealth agreed to sell its diabetes business to Cardinal Health for $235 million in cash. Management says this sharpens focus on sleep, respiratory and home medical equipment, and gives money to pay down debt and reinvest in the core.
This is a major new strategic move that could support the stock by simplifying the company.
New CFO named as leadership changes AdaptHealth named Harriss Currie as its new chief financial officer, replacing Jason Clemens. A fresh CFO could bring new discipline, but the change comes right after a guidance shock, so investors may wait to see how it plays out.
A new CFO is a new event that could affect how investors view the company's financial credibility.

August 202616 Jul – 8 Sep 2026

▼2▲1

AdaptHealth Cuts 2026 Outlook, Sells Diabetes Unit, Swaps CFO

Q2 miss and huge 2026 guidance cut AdaptHealth badly missed second-quarter sales and profit, then slashed its 2026 revenue forecast to about $2.87 billion from $3.45–3.52 billion. The stock fell roughly 42–46% as investors lost confidence in how fast the core business is growing.
This is the single biggest new force behind AHCO's price drop this period.
Negative free cash flow and securities investigation Free cash flow turned negative at $48.4 million for the first half, down from positive $73.3 million a year earlier, partly due to a costly West Coast contract. A law firm opened an investigation into whether AdaptHealth misled investors, adding legal uncertainty.
Cash flow weakness and legal risk are new, concrete reasons investors are selling.
Selling diabetes unit to Cardinal Health for $235 million AdaptHealth agreed to sell its diabetes business to Cardinal Health for $235 million in cash. Management says this sharpens focus on sleep, respiratory and home medical equipment, and gives money to pay down debt and reinvest in the core.
This is a major new strategic move that could support the stock by simplifying the company.
New CFO named as leadership changes AdaptHealth named Harriss Currie as its new chief financial officer, replacing Jason Clemens. A fresh CFO could bring new discipline, but the change comes right after a guidance shock, so investors may wait to see how it plays out.
A new CFO is a new event that could affect how investors view the company's financial credibility.

Latest16 Jul – 8 Sep 2026

▼2▲1

AdaptHealth Cuts 2026 Outlook, Sells Diabetes Unit, Swaps CFO

Q2 miss and huge 2026 guidance cut AdaptHealth badly missed second-quarter sales and profit, then slashed its 2026 revenue forecast to about $2.87 billion from $3.45–3.52 billion. The stock fell roughly 42–46% as investors lost confidence in how fast the core business is growing.
This is the single biggest new force behind AHCO's price drop this period.
Negative free cash flow and securities investigation Free cash flow turned negative at $48.4 million for the first half, down from positive $73.3 million a year earlier, partly due to a costly West Coast contract. A law firm opened an investigation into whether AdaptHealth misled investors, adding legal uncertainty.
Cash flow weakness and legal risk are new, concrete reasons investors are selling.
Selling diabetes unit to Cardinal Health for $235 million AdaptHealth agreed to sell its diabetes business to Cardinal Health for $235 million in cash. Management says this sharpens focus on sleep, respiratory and home medical equipment, and gives money to pay down debt and reinvest in the core.
This is a major new strategic move that could support the stock by simplifying the company.
New CFO named as leadership changes AdaptHealth named Harriss Currie as its new chief financial officer, replacing Jason Clemens. A fresh CFO could bring new discipline, but the change comes right after a guidance shock, so investors may wait to see how it plays out.
A new CFO is a new event that could affect how investors view the company's financial credibility.